Skip to content
10-Q

Quarterly Report

PURE Bioscience, Inc. PURE

0001641172-25-015245

← back to feed
Filed
Jun 16, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Jun 16, 2025 111.89M sh
Current Liabilities Q3 2025 · Apr 30, 2025 $972K
Current Liabilities Q3 2025 · Jul 31, 2024 $733K
Total Liabilities Q3 2025 · Apr 30, 2025 $5.87M
Total Liabilities Q3 2025 · Jul 31, 2024 $3.68M
Current Assets Q3 2025 · Apr 30, 2025 $1.05M
Current Assets Q3 2025 · Jul 31, 2024 $805K
Total Assets Q3 2025 · Apr 30, 2025 $1.06M
Total Assets Q3 2025 · Jul 31, 2024 $818K
Cash And Equivalents Q3 2025 · Jul 31, 2024 $349K
Cash And Equivalents Q3 2025 · Apr 30, 2024 $442K
Shares Diluted Q3 2025 · Apr 30, 2024 111.86M sh
Shares Diluted Q3 2025 · Apr 30, 2024 111.86M sh
Operating Cash Flow Q3 2025 · Apr 30, 2024 −$1.94M
Stockholders Equity Q3 2025 · Apr 30, 2024 −$2.15M
Stockholders Equity Q3 2025 · Jan 31, 2024 −$1.32M
Stockholders Equity Q3 2025 · Jul 31, 2023 $272K
Eps Diluted Q3 2025 · Apr 30, 2024 −$0.01
Eps Diluted Q3 2025 · Apr 30, 2024 −$0.03
Eps Basic Q3 2025 · Apr 30, 2024 −$0.01
Eps Basic Q3 2025 · Apr 30, 2024 −$0.03
Sga Expense Q3 2025 · Apr 30, 2024 $998K
Sga Expense Q3 2025 · Apr 30, 2024 $3.14M
Rd Expense Q3 2025 · Apr 30, 2024 $77K
Rd Expense Q3 2025 · Apr 30, 2024 $233K
Net Income Q3 2025 · Apr 30, 2024 −$857K
Net Income Q3 2025 · Apr 30, 2024 −$2.59M
Operating Income Q3 2025 · Apr 30, 2024 −$817K
Operating Income Q3 2025 · Apr 30, 2024 −$2.49M
Gross Profit Q3 2025 · Apr 30, 2024 $258K
Gross Profit Q3 2025 · Apr 30, 2024 $877K
Cost Of Revenue Q3 2025 · Apr 30, 2024 $183K
Cost Of Revenue Q3 2025 · Apr 30, 2024 $612K
Revenue Q3 2025 · Apr 30, 2024 $441K
Revenue Q3 2025 · Apr 30, 2024 $1.49M